In a multivariate analysis of NF1-MPNSTs which evaluated margin status, adjuvant and neoadjuvant treatment, age, initial tumor size, presence of metastasis at diagnosis, initial location of the tumor, and gender, aberrant ATRX expression was found to be an independent poor prognostic factor with a hazard ratio of 5.3 (95%CI:1.367–20.433) (Table 4). Here, ATRX is linked to neoplasm.